Background/Aims: The aim was to examine added benefits of a Comprehensive, Individualized, Person-Centered Management (CI-PCM) program to memantine treatment. Methods: This was a 28-week, clinician-blinded, randomized, controlled, parallel-group study, with a similar study population, similar eligibility criteria, and a similar design to the memantine pivotal trial of Reisberg et al. [N Engl J Med 2003;348:1333-1341]. Twenty eligible community-residing Alzheimer disease (AD) subject-caregiver dyads were randomized to the CI-PCM program (n = 10) or to usual community care (n = 10). Primary outcomes were the New York University Clinician's Interview-Based Impression of Change Plus Caregiver Input (NYU-CIBIC-Plus), assessed by one clinician set, and an activities of daily living inventory, assessed by a separate clinician set at baseline and at weeks 4, 12, and 28. Results: Primary outcomes showed significant benefits of the CI-PCM program at all post-baseline evaluations. Improvement on the NYU-CIBIC-Plus in the management group at 28 weeks was 2.9 points over the comparator group. The memantine 2003 trial showed an improvement of 0.3 points on this global measure in memantine-treated versus placebo-randomized subjects at 28 weeks. Hence, globally, the management program intervention benefits were 967% greater than memantine treatment alone. Conclusion: These results are approximately 10 times those usually observed with both nonpharmacological and pharmacological treatments and indicate substantial benefits with the management program for advanced AD persons.

Keywords:
Dementia, Activities of daily living, Behavioral symptoms, Comprehensive health care, Caregivers, Community health care, Patient-centered care, Person-centered therapy, Delivery of health care, Community health education
1.
Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ; for the Memantine Study Group: Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med 2003;348:1333-1341.
2.
Winblad B, Poritis N: Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriatr Psychiatry 1999;14:135-146.
3.
Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I; Memantine Study Group: Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA 2004;291:317-324.
4.
Finkel SI (guest ed): Behavioral and psychological signs and symptoms of dementia: implications for research and treatment. Proceedings of an international consensus conference. Lansdowne, Virginia, April 1996. Int Psychogeriatr 1996;8(suppl 3):215-552.
5.
Finkel SI, Burns A (guest eds): Behavioral and Psychological Symptoms of Dementia (BPSD): a clinical and research update. Int Psychogeriatr 2000;12(suppl 1):9-424.
6.
Reisberg B, Monteiro I, Torossian C, Auer S, Shulman MB, Ghimire S, Boksay I, Guillo BenArous F, Osorio R, Vengassery A, Imran S, Shaker H, Noor S, Naqvi S, Kenowsky S, Xu J: The BEHAVE-AD assessment system: a perspective, a commentary on new findings, and a historical review. Dement Geriatr Cogn Disord 2014;38:89-146.
7.
Brodaty H, McGilchrist C, Harris L, Peters KE: Time until institutionalization and death in patients with dementia. Role of caregiver training and risk factors. Arch Neurol 1993;50:643-650.
8.
Mittelman MS, Haley WE, Clay OJ, Roth DL: Improving caregiver well-being delays nursing home placement of patients with Alzheimer disease. Neurology 2006;67:1592-1599.
9.
Metitieri T, Zanetti O, Geroldi C, Frisoni GB, De Leo D, Dello Buono M, Bianchetti A, Trabucchi M: Reality orientation therapy to delay outcomes of progression in patients with dementia. A retrospective study. Clin Rehabil 2001;15:471-478.
10.
Brotons M, Marti P: Music therapy with Alzheimer's patients and their family caregivers: a pilot project. J Music Ther 2003;40:138-150.
11.
Ancoli-Israel S, Martin JL, Gehrman P, Shochat T, Corey-Bloom J, Marler M, Nolan S, Levi L: Effect of light on agitation in institutionalized patients with severe Alzheimer disease. Am J Geriatr Psychiatry 2003;11:194-203.
12.
Zeisel J, Silverstein NM, Hyde J, Levkoff S, Lawton MP, Holmes W: Environmental correlates to behavioral health outcomes in Alzheimer's special care units. Gerontologist 2003;43:697-711.
13.
Neal M, Briggs M: Validation therapy for dementia. Cochrane Database Syst Rev 2003;CD001394.
14.
Teri L, Gibbons LE, McCurry SM, Logsdon RG, Buchner DM, Barlow WE, Kukull WA, LaCroix AZ, McCormick W, Larson EB: Exercise plus behavioral management in patients with Alzheimer disease: a randomized controlled trial. JAMA 2003;290:2015-2022.
15.
Luijpen MW, Scherder EJ, Van Someren EJ, Swaab DF, Sergeant JA: Non-pharmacological interventions in cognitively impaired and demented patients: a comparison with cholinesterase inhibitors. Rev Neurosci 2003;14:343-368.
16.
Olazarán J, Reisberg B, Clare L, Cruz I, Peña-Casanova J, Del Ser T, Woods B, Beck C, Auer S, Lai C, Spector A, Fazio S, Bond J, Kivipelto M, Brodaty H, Rojo JM, Collins H, Teri L, Mittelman M, Orrell M, Feldman HH, Muñiz R: Nonpharmacological therapies in Alzheimer's disease: a systematic review of efficacy. Dement Geriatr Cogn Disord 2010;30:161-178.
17.
Reisberg B, Franssen EH, Souren LEM, Auer SR, Akram I, Kenowsky S: Evidence and mechanisms of retrogenesis in Alzheimer's and other dementias: management and treatment import. Am J Alzheimers Dis Other Demen 2002;17:202-212.
18.
Reisberg B, Javed A, Kenowsky S, Auer SR: Alzheimer's disease; in Zaretsky HH, Richter EF III, Eisenberg MG (eds): Medical Aspects of Disability, ed 3. New York, Springer, 2005, pp 79-118.
19.
Kitwood T, Bredin K: Towards a theory of dementia care: personhood and well-being. Ageing Soc 1992;12:269-287.
20.
Kenowsky S: What aspects of behavioral disturbances are important to caregivers? Perspective of a family caregiver. Int Psychogeriatr 1996;8(suppl 3):449-453.
21.
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH harmonized tripartite guideline: guideline for good clinical practice. 1996. E6(R1).http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf.
22.
World Medical Association: World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 2013;310:2191-2194.
23.
American Psychiatric Association: Diagnostic and Statistical Manual for Mental Disorders, ed 4, text revision (DSM-IV-TR). Washington, American Psychiatric Association, 2000.
24.
McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
25.
Reisberg B, Ferris SH, de Leon MJ, Crook T: The Global Deterioration Scale for assessment of primary degenerative dementia. Am J Psychiatry 1982;139:1136-1139.
26.
Sclan SG, Reisberg B: Functional assessment staging (FAST) in Alzheimer's disease: reliability, validity and ordinality. Int Psychogeriatr 1992;4:55-69.
27.
Folstein MF, Folstein SE, McHugh PR: “Mini-mental state.” A practical method for grading the cognitive state of persons for the clinician. J Psychiatr Res 1975;12:189-198.
28.
Rosen WG, Terry RD, Fuld PA, Katzman R, Peck A: Pathological verification of ischemic score in differentiation of dementias. Ann Neurol 1980;7:486-488.
29.
Department of Health and Human Services National Institute of Health: Alzheimer's Disease: Unraveling the Mystery. NIH Publication Number 02-3782, December 2002. http://www.nia.nih.gov/HealthInformation/Publications/.
30.
Reisberg B, Kenowsky S, Franssen EH, Auer SR, Souren LEM: President's report: towards a science of Alzheimer's disease management: a model based upon current knowledge of retrogenesis. Int Psychogeriatr 1999;11:7-23.
31.
Reisberg B, Franssen EH: Clinical stages of Alzheimer's disease; in de Leon MJ (ed): An Atlas of Alzheimer's Disease. Carnforth, Parthenon, 1999, pp 11-20.
32.
Reisberg B, London E, Ferris SH, Borenstein J, Scheier L, de Leon MJ: The Brief Cognitive Rating Scale: language, motoric, and mood concomitants in primary degenerative dementia. Psychpharmacol Bull 1983;19:702-708.
33.
Reisberg B, Ferris SH, de Leon MJ, Sinaiko E, Franssen E, Kluger A, Mir P, Borenstein J, George AE, Shulman E, Steinberg G, Cohen J: Stage-specific behavioral, cognitive, and in vivo changes in community residing subjects with age-associated memory impairment and primary degenerative dementia of the Alzheimer type. Drug Dev Res 1988;15:101-114.
34.
Reisberg B, Auer SR, Monteiro I, Franssen E, Kenowsky S: A rational psychological approach to the treatment of behavioral disturbances and symptomatology in Alzheimer's disease based upon recognition of the developmental age. Int Acad Biomed Drug Res 1998;13:102-109.
35.
Teri L, Logsdon RG, McCurry SM: Nonpharmacologic treatment of behavioral disturbance in dementia. Med Clin North Am 2002;86:641-656.
36.
Reisberg B, Franssen E, Sclan SG, Kluger A, Ferris SH: Stage specific incidence of potentially remediable behavioral symptoms in aging and Alzheimer's disease: a study of 120 patients using the BEHAVE-AD. Bull Clin Neurosci 1989;54:95-112.
37.
McKitrick LA, Camp C, Black FW: Prospective memory intervention in Alzheimer's disease. J Gerontol 1992;47:337-343.
38.
Franssen EH, Souren LEM, Torossian CL, Reisberg B: Equilibrium and limb coordination in mild cognitive impairment and mild Alzheimer's disease. J Am Geriatr Soc 1999;47:463-469.
39.
Franssen EH, Kluger A, Torossian CL, Reisberg B: The neurologic syndrome of severe Alzheimer's disease: relationship to functional decline. Arch Neurol 1993;50:1029-1039.
40.
Souren LEM, Franssen EM, Reisberg B: Contractures and loss of function in patients with Alzheimer's disease. J Am Geriatr Soc 1995;43:650-655.
41.
Reisberg B, Saeed MU: Alzheimer's disease; in Sadovoy J, Jarvik LF, Grossberg GT, Meyers BS (eds): Comprehensive Textbook of Geriatric Psychiatry, ed 3. New York, Norton, 2004, pp 449-509.
42.
Reisberg B: Global measures: utility in defining and measuring treatment response in dementia. Int Psychogeriatr 2007;19:421-456.
43.
Galasko DR, Schmitt FA, Jin S, Saxton J, Bennett D, Sano M, Ferris SH: Detailed assessment of cognition and activities of daily living in moderate to severe Alzheimer's disease. Neurobiol Aging 2000;21:(suppl 1):168.
44.
Panisset M, Roudier M, Saxton J, Boller F: Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol 1994;51:41-45.
45.
Monteiro IM, Boksay I, Auer SR, Torossian C, Ferris SH, Reisberg B: Addition of a frequency-weighted score to the Behavioral Pathology in Alzheimer's Disease Rating Scale: the BEHAVE-AD-FW: methodology and reliability. Eur Psychiatry 2001;16(suppl 1):5s-24s.
46.
Teri L, Truax P, Logsdon R, Uomoto J, Zarit S, Vitaliano PP: Assessment of behavioral problems in dementia: the revised memory and behavior problems checklist (RMBPC). Psychol Aging 1992;7:622-631.
47.
Reisberg B, Franssen E, Souren L, Kenowsky S, Janjua K, Veigne S, Guillo Benarous F, Singh S, Khizar A, Shah U, Shah R, Bhandal A, Auer S: Alzheimer's disease; in Moroz A, Flanagan SR, Zaretsky H (eds): Medical Aspects of Disability, ed 5. New York, Springer, 2017, pp 31-90.
© 2017 S. Karger AG, Basel
2017
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.